A putative placebo comparison of the SCOPE and LIFE trials
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial and the Study on Cognition and Prognosis in the Elderly (SCOPE) superficially produced comparable outcomes, with effects on stroke greater than those anticipated from blood pressure (BP) lowering alone. This, however, igno...
Main Authors: | Peter A Meredith, Lilian S Murray, John JV McMurray |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi - SAGE Publishing
2004-06-01
|
Series: | Journal of the Renin-Angiotensin-Aldosterone System |
Online Access: | https://doi.org/10.3317/jraas.2004.011 |
Similar Items
-
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
by: John JV McMurray
Published: (2001-06-01) -
Introduction
by: John JV McMurray
Published: (2004-03-01) -
Angiotensin inhibition in heart failure
by: John JV McMurray
Published: (2004-03-01) -
Angiotensin receptor blockers in heart failure
by: Jan Östergren, et al.
Published: (2003-09-01) -
Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction
by: John McMurray, et al.
Published: (2000-06-01)